Variables Total (N, %) Dead (N, %) Active (N, %) Log-rank P
Functional status       0.000
Working 434 (55.4%) 12 (13.8%) 422 (60.5%)
Ambulatory 242 (30.9%) 37 (42.5%) 205 (29.4%)
Bedridden 108 (13.8%) 38 (43.7%) 70 (10.0%)
WHO staging       0.000
Stage I & II 329 (42.0%) 10 (11.5%) 319 (45.8%)
Stage III 327 (41.7%) 38 (43.7%) 289 (41.5%)
Stage IV 128 (16.3%) 39 (44.8%) 89 (12.8%)
BMI for age       0.000
≥18.5 Kg/m2 335 (42.7%) 23 (26.4%) 312 (44.8%)
< 18.5 Kg/m2 449 (57.3%) 64 (73.6%) 385 (55.2%)
ART regimen       0.429
d4T/3TC/NVP 221 (28.2%) 25 (28.7%) 196 (28.1%)
d4T/3TC/EFV 78 (9.9%) 7 (8.0%) 71 (10.2%)
AZT/3TC/NVP 202 (25.8%) 25 (28.7%) 177 (25.4%)
AZT/3TC/EFV 50 (6.4%) 5 (5.7%) 45 (6.5%)
TDF/3TC/EFV 118 (15.1%) 10 (11.5%) 108 (15.5%)
TDF/3TC/NVP 115 (14.7%) 15 (17.2%) 100 (14.3%)
Cotrimoxazole       0.032
Given 658 (83.9%) 66 (75.9%) 592 (84.9%)
Not given 126 (16.1%) 21 (24.1%) 105 (15.1%)
INH Given       0.000
Given 61 (7.8%) 20 (23.0%) 41 (5.9%)
Not given 723 (92.2%) 67 (77.0%) 656 (98.3%)
TB co-infected       0.015
Yes 311 (39.7%) 45 (51.7%) 266 (38.2%)
No 473 (60.3%) 42 (48.3%) 431 (61.8%)
Weight (Kg) ‡ 49.9 (44−56) 43.8 (37−50) 50.7 (45−56) 0.000
CD4 count (cells/ μL) ‡ 150 (102−196) 72 (31−99) 160 (116−206) 0.000
Hemoglobin (g/dL) ‡& 11.4 (10.0−13.0) 9.9 (7.9−11.3) 11.6 (10.3−13.1) 0.000
Table 2: Clinical and laboratory markers of adult PLHIV receiving ART in Somali region, Ethiopia [N=784], May 2013